Judging from body language I would not think they are working on heparins for Teva, my bet would be antibodies. but who knows?
Unlike Momenta, Procognia is not a drug developing company. They are more of sub contractors for glycoanalysis projects. Customers can pay for analysis work or make them a minor partner (Teva).
Bristol is still evaluating the technology and it is not known yet if they will have a long term agreement like Teva.
The third agreement is with Nutricognia in the R&D and manufacture of nutritional commodities, they will get fat royalties for 15 years but this is not a big issue for the time being.
They also have a marketing agreement with Qiagen for their low resolution device for scientific research, not a big issue either.
Unlike Momenta, Procognia is not a drug developing company. They are more of sub contractors for glycoanalysis projects. Customers can pay for analysis work or make them a minor partner (Teva).
Bristol is still evaluating the technology and it is not known yet if they will have a long term agreement like Teva.
The third agreement is with Nutricognia in the R&D and manufacture of nutritional commodities, they will get fat royalties for 15 years but this is not a big issue for the time being.
They also have a marketing agreement with Qiagen for their low resolution device for scientific research, not a big issue either.
Recent PLX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2026 11:06:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 10:57:15 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/30/2026 08:35:11 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 08:30:39 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 03/30/2026 09:31:32 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/18/2026 11:12:44 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/18/2026 10:56:54 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/09/2026 11:51:13 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 10:10:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2026 03:09:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2026 11:56:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/23/2025 12:25:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 09:34:55 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 11:58:56 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 11:54:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2025 09:44:01 PM
- Protalix BioTherapeutics Inc stock plunges after CHMP rejects alternative Elfabrio dosing regimen • IH Market News • 10/17/2025 02:50:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2025 12:08:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2025 09:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2025 09:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2025 09:00:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2025 09:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2025 09:00:14 PM
